MedTrace Logo

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

NCT05763459 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-06-26

No results posted yet for this study

Summary

This study follows an open-label, single arm design with two periods with rosuvastatin, digoxin and ABBV-CLS-7262

Conditions

  • Healthy

Interventions

DRUG

ABBV-CLS-7262

Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Calico Life Sciences LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-24
Primary Completion
2023-05-08
Completion
2023-06-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05763459 on ClinicalTrials.gov